Pre-made Navivumab benchmark antibody ( Whole mAb, anti-Influenza A HA therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Navivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-368-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Navivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody
INN Name	Navivumab
Target	Influenza A HA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preclinical
Est. Status	Discontinued
100% SI Structure	4r8w:HL
99% SI Structure	6fg1:HL/6fg2:HL
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Celltrion
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections
Development Tech	na